MTOR and ovarian carcinoma: Moreover, PI3Kα and Twist positive CTCs could be an attractive therapeutic target, since PI3K/Akt/mTOR pathway inhibitors are currently being investigated for ovarian cancer among several preclinical studies and also a few ongoing clinical trials [32] (NCT01623349, NCT02476955).